Lianhetech plans to invest ¥500 million to Lianhetech (Dezhou), a pesticide production subsidiary
May 29, Lianhetech announced that in order to further meet the business development needs of Lianhetech (Dezhou) ,Lianhetech plans to use its own capital, ¥ 50 million to invest Lianhetech (Dezhou).After the completion of the capital increase, Lianhetech (Dezhou) registered capital increased from ¥1028.88 million to ¥1528.88 million
Lianhetech said that the company used its own funds to increase the capital of the subsidiary, in order to meet the needs of the subsidiary Lianhetech's (Dezhou) business development, is conducive to promoting the development of the company's business
2026-10-11
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Renaissance BioScience Receives Genome BC Funding to Extend RNAi Biopesticide Platform to Target Soil-Dwelling Crop Pests
-
The project with an investment of ¥105 million and an annual output of 4000 tons of Propargite is to be built
-
Brazil's Agriconnection uses a new model to import and direct sell pesticides, with revenue exceeding $340 million
-
The Indian biopesticide market will grow at a CAGR of 9.38%
-
China's insecticide import and export data for June
-
Jiangsu TrustChem’s degradable pesticide packaging bottle won the domestic and international invention patent authorization
-
Hebang Biological intends to increase its stake in Australian listed company AEV and achieve control
-
The operating rate of Brazil's chemical industry has deteriorated: at just 58%, the latest figure is the lowest since 1990
-
Adama President and CEO Change! He took office on October 1
-
BAL became the first local company in India to register a 96% Haloxyfop-R-methyl ester Technical
Recommend Reading
-
Cipla CEO Calls Tirzepatide a High-Science Product with Strong Market Outlook
-
Pfizer Seen Holding Strategic Edge in Bidding Battle for Metsera
-
Novo Nordisk Enters High-Stakes Bidding War with Pfizer for Metsera
-
AstraZeneca’s Wainua Fails Phase III Heart Trial, Wiping Out About $27 Billion in Market Value
-
Pfizer Sues Metsera and Novo Nordisk Over Rival Obesity Drug Strategy
-
Insufficient Cost and Demand Support; PTA Prices to Weaken
-
Vera’s New Kidney Drug Wins FDA Approval, Carrying a $425,000 Annual Price
-
South Korea Expands Mandatory GMO Labeling to Highly Processed Foods
-
Polyester Bottle Chip Spot Price Rises on the 14th
-
Bayer and Syngenta Score Consecutive Regulatory and Legal Wins in the U.S.
- Hot Searches
- chemical suppliers & distributors
- polycaprolactam polymer registered under number 25038-54-4
- where to get reta peptides
- propylene pricing
- foxo4 peptide for sale
- urea fertilizer price
- sulfuric acid price per litre
- sodium chlride
- thymosin alpha 1 price
- uranium hexafluoride
- na 931 for sale
- sr 17018 for sale 1 gram